LEIDEN, NETHERLANDS--(Marketwire - January 31, 2011) - Biotech company Pharming Group NV
("Pharming") (NYSE Euronext: PHARM) today announces that it has
discontinued the
funding of DNage.

In July 2010, Pharming announced the completion of the spin-off of
its
subsidiary DNage. As part of the spin- off agreement, Pharming agreed to
provide
DNage with an undisclosed,limited bridge funding for a specified term, to
allow
DNage time to seek new investors. DNage has been unable to secure new
investors
and its shareholders have now decided to put DNage into voluntary
liquidation.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of
unmet
medical needs. Ruconest™ (Rhucin® in non-European
territories) is a
recombinant human C1 inhibitor approved for the treatment of angioedema
attacks
in patients with HAE in all 27 EU countries plus Norway, Iceland
and
Liechtenstein. The product is also under development for follow-on
indications,
i.e. antibody-mediated rejection (AMR) and delayed graft function
(DGF)
following kidney transplantation. The advanced technologies of the
Company
include innovative platforms for the production of protein
therapeutics,
technology and processes for the purification and formulation of these
products.
Additional information is available on the Pharming website,
www.pharming.com.

This press release contains forward looking statements that involve
known and
unknown risks, uncertainties and other factors, which may cause the
actual
results, performance or achievements of the Company to be materially
different
from the results, performance or achievements expressed or implied by
these
forward looking statements.

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.